

ADOPTED: DD MM 201X

PUBLISHED: dd mmmm yyyy

AMENDED: dd mmmm yyyy

doi:10.2903/j.efsa.20YY.NNNN

Guidance on the assessment of the safety of feed additives for the target species

EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Guido Rychen, Gabriele Aquilina, Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos, Georges Bories, Andrew Chesson, Pier Sandro Cocconcelli, Gerhard Flachowsky, Jürgen Gropp, Boris Kolar, Maryline Kouba, Marta López Alonso, Secundino López Puente, Baltasar Mayo, Fernando Ramos, Maria Saarela, Roberto Edoardo Villa, Robert John Wallace, Pieter Wester, Montserrat Anguita, Jaume Galobart, Matteo L. Innocenti and Laura Martino

Endorsed for public consultation on 22 March 2017

Abstract

© European Food Safety Authority, 20YY

Keywords: safety, target species

Requestor: EFSA

Question number: EFSA-Q-2016-00553

Correspondence: feedap@efsa.europa.eu

22 **Panel members:** Gabriele Aquilina, Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos,
23 Georges Bories, Andrew Chesson, Pier Sandro Cocconcelli, Gerhard Flachowsky, Jürgen Gropp, Boris
24 Kolar, Maryline Kouba, Marta López Alonso, Secundino López Puente, Alberto Mantovani, Baltasar
25 Mayo, Fernando Ramos, Guido Rychen, Maria Saarela, Roberto Edoardo Villa, Robert John Wallace
26 and Pieter Wester.

27 **Acknowledgements:** The Panel wishes to thank the following for the support provided to this
28 scientific output:

29 **Suggested citation:** EFSA FEEDAP Panel (EFSA Panel on additives and products or substances used
30 in animal feed), 20YY. Guidance on the assessment of the safety of feed additives for the target
31 species. EFSA Journal 20YY;volume(issue):NNNN, 22 pp. doi:10.2903/j.efsa.20YY.NNNN

32 **ISSN:** 1831-4732

33 © 20YY European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on
34 behalf of European Food Safety Authority.

35 This is an open access article under the terms of the [Creative Commons Attribution-NoDerivs](#) License,
36 which permits use and distribution in any medium, provided the original work is properly cited and no
37 modifications or adaptations are made.



The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.



38

39 Table of contents

40		
41	Abstract.....	1
42	Background and Terms of reference	4
43	Scope of the guidance	4
44	1. Introduction.....	4
45	2. Additives for which safety can be presumed without additional studies.....	5
46	3. Extensive literature search for studies with target animals.....	5
47	4. Toxicity data from repeated dose studies in laboratory animals.....	6
48	5. Tolerance studies in target animals	7
49	5.1. Test item.....	8
50	5.2. Experimental groups	8
51	5.3. Animals	8
52	5.4. Statistical considerations	9
53	5.4.1. Design of the experiment	9
54	5.4.2. Sample size	9
55	5.4.3. Statistical analysis	10
56	5.5. End-points.....	10
57	5.6. Duration of the tolerance study.....	11
58	5.7. Requirement for tolerance studies.....	13
59	5.8. Reporting	15
60	6. Toxicological studies	17
61	7. Interactions <i>in vivo</i>	17
62	8. Microbial studies	17
63	References.....	19
64	Abbreviations	20
65	Appendix A – Trial Protocol data sheet	21
66		
67		

68 **Background and Terms of reference**

69 Regulation (EC) No 1831/2003 establishes the rules governing the Community authorisation of
70 additives for use in animal nutrition. Moreover, Regulation (EC) No 429/2008 provides detailed rules
71 for the implementation of Regulation (EC) No 1831/2003 as regards the preparation and the
72 presentation of applications and the assessment and the authorisation of feed additives.

73 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) has adopted
74 a series of guidance documents which aim at complementing Regulation (EC) No 429/2008 to support
75 applicants in the preparation and submission of technical dossiers for the authorisation of additives for
76 use in animal nutrition according to Regulation (EC) No 1831/2003.

77 The European Food Safety Authority (EFSA) asked its FEEDAP Panel to:

- 78 1. identify from the current guidance documents, those that need to be updated, taking into
79 consideration the most recent scientific developments and the experience gained in the
80 assessment of feed additives;
- 81 2. update the guidance documents in need of revision accordingly; this activity can be conducted
82 in different rounds of activities on the basis of the priorities identified and on the feasibility of
83 the revision according the resources available;
- 84 3. taking into account the sensitivity and the relevance of some of the guidance documents
85 under revision and the entity of the revision itself (e.g. substantial or not), consider initiatives
86 like preparatory info-sessions or public consultations of the draft guidance documents. The
87 relevant comments received in either step will have to be considered and addressed if
88 appropriate in the final version of the guidance documents.

89 The first of the terms of reference was addressed by a statement of the FEEDAP Panel (EFSA FEEDAP
90 Panel, 2016), in which it was identified the need to update most of the guidance documents that it
91 produced and set priorities for this update.

92 This output addresses the second and third terms of reference with regards to the update of the
93 guidance documents dealing with the assessment of the safety of feed additives for the target
94 species.

95 **Scope of the guidance**

96 This guidance document is part of a series of documents intended to assist the applicant in the
97 preparation and the presentation of its application for authorisation of a feed additive, as foreseen in
98 Article 7.6 of Regulation (EC) No 1831/2003. This document does not substitute for the obligation of
99 an applicant to comply with the requirements of Regulation (EC) No 1831/2003 and its implementing
100 rules.

101 Applicants should justify the omission from the dossier of any data or any deviations from the
102 requirements detailed in this guidance.

103 **1. Introduction**

104 Studies involving animals should respect the rules on animal welfare laid down by European Union
105 legislation, particularly those listed in Directive 63/2010/EU, and they should not be repeated if
106 available elsewhere. The use of methods refining or replacing the tests using experimental animals or
107 reducing the number of animals used in these tests shall be encouraged. Such methods must provide
108 the same level of assurance as the methods they aim to replace.

109 For certain additives, safety for the target animals can be presumed without the need for specific
110 information. For all other additives, safety for the target animals can be assessed as a first step by
111 extensive literature searches for studies on target animals. If safety cannot be established by
112 literature search, the applicant can use toxicity data (either existing or new) from repeated dose
113 studies in laboratory animals or conduct tolerance studies in target animals.

114 2. Additives for which safety can be presumed without additional 115 studies

116 For the following additives, safety for the target animals can be presumed without the need for
117 additional studies:

- 118 - additives for which no significant amounts of the active substance(s) (or related substances)
119 or the active agent(s) remain in the feed at time of feeding.
- 120 - silage additives where it can be demonstrated that the active substance(s) and agent(s) occur
121 as normal constituents of silage and use of the additive does not substantially increase their
122 concentration compared to silage prepared without use of the additive (i.e. where there is no
123 substantial change in exposure).
- 124 - microorganisms satisfying the requirements of the qualified presumption of safety (QPS)
125 approach to safety assessment ([EFSA, 2007](#); [EFSA BIOHAZ Panel, 2017](#)).
- 126 - nutritional additives assessed and authorised following the provisions of Regulation (EC) No
127 1831/2003.
- 128 - nutritional additives not already authorised:
 - 129 ○ when the active substance is sufficiently purified. A product will be considered as
130 sufficiently purified if the unidentified fraction would not contribute to more than 1 %
131 when the inclusion rate does not exceed 1,000 mg additive/kg complete feed. Higher
132 inclusion rates would need a higher degree of purity (e.g., 10,000 mg additive/kg
133 feed would correspond to 99.9%).
 - 134 ○ when the additive is produced by fermentation using a production organism that (i)
135 satisfies the requirements of the QPS approach to safety assessment, or (ii) is a
136 genetically modified microorganism (GMM) for which the recipient strain is considered
137 by EFSA to qualify for the QPS approach to safety assessment and for which the
138 molecular/genetic characterisation does not give rise to concern.

139 3. Extensive literature search for studies with target animals

140 Extensive literature searches should be used as a first step to provide information on the safety of the
141 feed additive under the proposed conditions of use. Relevant information sources should be searched
142 in a structured manner. The applicant should make reasonable efforts to locate all sources of relevant
143 information and provide reasons for the selection of such sources. Bibliographic databases (including
144 at least agricultural/aquacultural and medical/veterinary databases) which record documents such as
145 journals, reports, conference proceedings and books should be searched. In addition the search
146 should consider sources other than bibliographic databases, such as reference lists of full-text journal
147 articles (e.g. reviews), websites of conferences or organisations.

148 Applicants should follow the recommendations of the "[Technical manual for performing electronic
149 literature searches in food and feed safety](#)" when performing the searches and documenting its
150 outcome. Moreover, applicants are encouraged to refer to Appendix D of the "[Tools for critically
151 appraising different study designs, systematic review and literature searches](#)" for assessing the quality
152 of the search.

153 The search methodology must be documented and reported in detail to ensure transparency and
154 enable the evaluation and replication of the strategy. The following must be reported:

155 For database searches:

- 156 - The name of the database and the service provider used;
- 157 - The date of the search, and the date range searched;
- 158 - Any limits placed on the search such as language or publication status;
- 159 - The full search strategy (all terms and set combinations) and the number of records retrieved.

160 For sources other than bibliographic databases:

161 1. Websites and journal table of contents

- 162 - The name of the resource (i.e. website name, the journal name in case of searching in
163 specific tables of contents);
- 164 - The URL (internet address);
- 165 - The date on which the search was conducted and the date range of the search, or the dates,
166 volumes and issues in the case of table of contents;
- 167 - The method of searching e.g. browsing, using the search engine or scanning tables;
- 168 - Any limits applied to the search (e.g. publication types);
- 169 - The search terms used and the number of relevant summary records or full-text documents
170 retrieved.

171 2. References lists

- 172 - The bibliographic details of the documents whose reference lists were scanned;
- 173 - The number of relevant bibliographic references retrieved.

174 The extensive literature search should cover at least the last 20 years. The list of relevant references
175 included should be compiled in a reference management software and provided in .RIS format. Copies
176 of the relevant papers should be provided. The applicant must ensure that terms and conditions
177 asserted by any copyright holder of publications or information submitted to EFSA are fully satisfied.
178 The applicant should consult with copyright licensing authorities (i.e. at national level) for guidance on
179 purchasing copyright licenses to reproduce any publications provided to EFSA. The applicant remains
180 solely responsible and liable for obtaining all necessary authorisations and rights to use, reproduce
181 and share the publications provided to EFSA.

182 The analysis of these data must establish that the active substance/agent in literature studies is
183 identical to that under application or, if not, would still allow conclusions on the additive under
184 application to be made; for additives produced by fermentation identity includes the production strain.
185 The concentration of the active substance/agent in feed should preferably exceed or at least cover
186 that proposed in the application. The target species covered in the literature search should be relevant
187 to the application. Application level, replicates, duration and zootechnical and clinical end-points
188 measured should allow a conclusion on the absence of adverse effects. This may be achieved by the
189 consideration of data from a number of independent studies. The literature search should also cover
190 all available toxicological end-points including genotoxicity.

191 If safety for one species/category is derived from literature studies and extrapolation to other
192 species/categories is required, the same principles as described under Section 5.7 should be followed.

193 **4. Toxicity data from repeated dose studies in laboratory animals**

194 For all additives with the exception of microorganisms, safety for target animals can be derived from
195 toxicological studies with oral administration in laboratory animals. These data should allow
196 establishing a lowest no observed adverse effect level (NOAEL) or a Benchmark dose level (e.g.,
197 BMDL₁₀). Ideally, subchronic or chronic toxicity studies should follow either the latest OECD protocols
198 or those in force at the time the study was made.

199 To derive a safe daily dose in the target species (mg/kg body weight (BW)), the NOAEL or BMDL₁₀,
200 expressed in mg/kg BW, is divided by an uncertainty factor of 100. The maximum safe concentration
201 in feed (M; mg/kg complete feed, as is basis) is obtained by dividing this safe daily dose by the
202 default feed intake (FI; expressed as a g dry matter (DM) per kg BW, Table 1). The resulting value
203 (mg additive/g DM feed) is multiplied by 1,000 to express the feed concentration per kg complete
204 feed and multiplied by 0.88 (or 0.945 for milk replacer for veal calves) to transform it to as is basis
205 (assuming 88% DM for complete feed and 94.5% for milk replacers).

206 Maximum safe concentration in feed = ((NOAEL/100)/FI) × 1,000 × 0.88

207 **Table 1:** Default values for daily feed intake scaled to body weight (g dry matter (DM)/kg body
208 weight) for the main animal species/categories

Animal category	Default values daily feed intake (g DM/kg body weight)	Values derived from	
		Body weight (kg)	Feed intake (kg DM/day)
Chicken for fattening	79	2	0.158
Laying hen	53	2	0.106
Turkey for fattening	59	3	0.176
Piglet	44	20	0.88
Pig for fattening	37	60	2.20
Sow lactating	30	175	5.28
Veal calf (milk replacer)	19	100	1.89
Cattle for fattening	20	400	8.0
Dairy cow	31	650	20.0
Salmon	18	0.12	0.0021
Dog	17	15	0.250
Cat	20	3	0.060
Ornamental fish	5	0.012	0.000054

209

210 The default values of feed intake in Table 1 are derived from estimated values of body weight and
 211 derived feed intake of the animals at the end of a tolerance study.

212 If specific toxicological data are not available, the thresholds of toxicological concern (TTC)¹ could be
 213 applied to flavouring additives only for which a Cramer structural class can be assigned. Assignment
 214 to a Cramer class is made using the Organisation for Economic Cooperation and Development (OECD)
 215 toolbox² or other commercial software. The “maximum acceptable feed concentrations” are derived
 216 from the thresholds of the TTC approach and based on the default values of feed intake shown in
 217 Table 1. Substances in Cramer class I would result in a maximum acceptable concentration in
 218 complete feed (mg/kg feed) between 0.3 and 1.5, for Cramer II between 0.1 and 0.5 and for Cramer
 219 III between 0.02 and 0.08.

220 5. Tolerance studies in target animals

221 If safety for the target species cannot be established at the maximum proposed dose by the methods
 222 described above, then *in vivo* studies in the relevant target species/categories are required. The
 223 number of tolerance studies required in different animal species/categories is described in Section 5.7.

224 The aim of the tolerance study is to provide a limited evaluation of short-term toxicity and a margin of
 225 safety³ of the additive to the target animals. It is recommended to combine the tolerance study with
 226 one of the efficacy trials, whenever possible.

227 Studies should be performed and documented according to appropriate quality standards and should
 228 respect the rules on animal welfare laid down by European Union legislation, particularly those listed
 229 in Directive 63/2010/EU. Trials should be compliant with the criteria established by a recognised,
 230 externally-audited, quality assurance scheme (e.g., good laboratory practice (GLP) in accordance with
 231 Directive 2004/10/EC). Evidence should be provided that the work was done by qualified personnel

¹ JECFA (FAO/WHO, 1996, Food additive series 35, IPCS, WHO Geneva); Barlow, S. 2005. Threshold of toxicological Concern (TTC). A tool for assessing substances of unknown toxicity present at low levels in the diet. ILSI Europe Concise Monograph Series.

Review of the Threshold of Toxicological Concern (TTC) approach and development of new TTC decision tree. EFSA supporting publication 2016: EN-1006. 50 pp. <http://onlinelibrary.wiley.com/doi/10.2903/sp.efsa.2016.EN-1006/pdf>
² <http://www.oecd.org/chemicalsafety/risk-assessment/theoecdqsartoolbox.htm>

³ Margin of safety: ratio of the highest tolerated additive concentration in feed and the highest use level proposed.

232 using appropriate facilities and equipment and responsible to a named study director. Studies
233 conducted outside the European Union must follow the same quality standards.

234 **5.1. Test item**

235 Tolerance studies should be based on the additive(s) for which application is made, except in cases
236 where a concentrated form of the additive(s) is recommended for testing (e.g., enzymes and
237 microorganisms). Any other deviations because of practical or other considerations should be justified.
238 A certificate of analysis of the test item used in the study should be provided. The additive could be
239 administered via feed or water for drinking depending on the conditions of use. The concentration of
240 the active substance(s) or agent(s) in the feedingstuffs/water should be confirmed by analysis.

241 **5.2. Experimental groups**

242 The design of a tolerance test includes a minimum of three groups:

- 243 - a control group
244 The diet/water of the control group should normally not contain the additive tested. However,
245 in case of additives for which a nutritional requirement exists, the control group should
246 receive the additive at the lowest requirement level.
- 247 - a use-level group
248 The diet/water of the use level group should normally contain the additive at the highest
249 recommended dose. For those additives for which a maximum dose is not recommended, the
250 highest typical use level should be used.
- 251 - an overdose group with a multi-fold of the use-level.

252 When the multi-fold dose tested is:

- 253 - ≥ 100 , test animals shall be routinely monitored for visual evidence of clinical signs,
254 performance characteristics and product quality where relevant. In this case a higher
255 concentration of the active substance or agent can be obtained by omitting or reducing the
256 amount of carrier. For fermentation products, the ratio of active agent(s)/substance(s) to the
257 other fermentation products must remain the same as in the additive.
- 258 - > 10 to <100 : in addition to the above, haematology and blood chemistry as described in
259 section 5.5 and other parameters likely to be related to the biological properties of the
260 additive.
- 261 - ≤ 10 : in addition to the above, gross pathology and histopathology if relevant, as described in
262 section 5.5. The study should be designed in such a way that a margin of safety for the
263 additive can be estimated. It is recognised that in some cases ethical and practical
264 considerations will prevent performing necropsy in all animals (e.g., pets, dairy cows, sows,
265 horses).

266 The setting conditions (e.g. temperature, light exposure) should be the same for the various groups
267 including housing, husbandry and diet/water administration.

268 **5.3. Animals**

269 Animals used should be healthy and preferably from a homogeneous group. Housing and husbandry
270 conditions should be adequate for the purpose of the study and conform to animal welfare
271 regulations. Preventive treatments with antibiotics/antimicrobials before the start of the trial should be
272 avoided. The acceptability of trials in which animals are treated with antibiotics/antimicrobials during
273 the course of the study will depend on a variety of factors, including the number of animals treated,
274 duration of the treatment, distribution between experimental groups and severity of the disease. The
275 acceptability of these studies will be assessed on a case by case basis. Any therapeutic/preventive
276 treatments should not interact with the proposed mode of action of the additive and should be
277 recorded individually. Studies with an abnormally high mortality in the control group will not be
278 accepted. This would be judged against European industry standards.

279 For food-producing animals, the conditions of the study should be such that optimal performance as
280 described for the breed (e.g., performance standards of broiler breeder companies) could be reached.
281 The higher the zootechnical performance of the animals in a given physiological stage, the more
282 sensitive the end-point(s) would be to adverse situations. Therefore, it is recommended to use in
283 studies with:

- 284 - chickens for fattening: only male birds
- 285 - laying hens: birds in the first third of the laying period
- 286 - dairy cows: high yielding animals in the first third of the lactation period
- 287 - growing pigs: weaned piglets of both sexes
- 288 - cattle: weaned male bovines at the beginning of the fattening period
- 289 - salmonids: juvenile phase

290 The recommended age/weight for the different species/categories at the start of the study is detailed
291 in Section 5.6.

292 **5.4. Statistical considerations**

293 **5.4.1. Design of the experiment**

294 The experimental unit is the smallest entity to which a given treatment is applied. If animals are
295 penned in groups and all the animals in the pen share the same feed source (and feed intake is not
296 measured individually), then the experimental unit for all parameters is the pen, not the individual
297 animal. For all endpoints which are measured on individual animals in a pen, a summary parameter of
298 the endpoint in the experimental unit should be used (e.g. mean for continuous measurements such
299 as body weight, median and counts for quantal measurements such as severity of an outcome or
300 mortality). Summary parameters should always be adjusted for losses (mortality/culling). The
301 distribution of losses within the treatment groups should be assessed to avoid the risk of introducing a
302 bias.

303 Experimental units allocated to the various experimental groups should not differ in a systematic way.
304 Therefore a recognised method of randomisation should be used to allocate treatments to the
305 experimental unit (e.g. pen, animal). A randomised block design should be preferably used to control
306 for experimental settings like location within facilities. The same design is also recommended in case
307 of large experiments to ensure concurrency in measurements/determination of endpoints across
308 treatments. Other designs might be also appropriate, in which case the applicant should justify the
309 rationale for the design chosen.

310 In case of a significant variability across animals of factors which could influence the outcome of the
311 study, animals should be stratified before being randomly allocated to pens/cages/treatments. These
312 factors might include initial body weight, age, stage of lactation, milk yield, parity, egg production.

313 A proper method for randomization should be used in order to allow allocation concealment (no a
314 priori knowledge of group assignment). In practice the randomization process must ensure that
315 investigator cannot influence the allocation of units to the various groups. It is recommended to
316 implement blinding of the care givers and investigators, where possible, for instance using a proper
317 codification of the treatment to be administered.

318 **5.4.2. Sample size**

319 Statistical considerations should be used to determine the size of the sample used to evaluate the
320 potential safety concerns. The setting of the null and alternative hypotheses should be done in light of
321 the problem formulation. Experiments aiming at demonstrating similarity between control and treated
322 groups should test for equivalence or non-inferiority (i.e. alternative hypothesis stating no or minimal
323 difference exists). Difference testing should be used when the purpose is to confirm superiority or
324 inferiority (i.e. alternative hypothesis stating a difference exists). Additional considerations need to
325 include: i) the magnitude of the effect that the study is designed to test and its variability; ii) the
326 expected direction of the effect; iii) an adequate statistical power and iv) the confidence level. The
327 magnitude of the effect considered biologically relevant (for difference testing) or the similarity range
328 (for equivalence testing) should be clearly indicated for each endpoint and the rationale for the choice

329 explained. For difference testing, when the direction of the effect is predictable, a one sided test
330 should be used. A two-sided test is recommended in all other cases.

331 The Type 2 (β) error measures the risk of non-detecting an effect (difference)/similarity (equivalence)
332 when it exists. As a guide it should be lower than or equal to 20% in general, and 25% for
333 experiments with ruminants, minor species, pets and non food-producing animals. Hence a power ($1-$
334 β) greater than or equal to 80% (75% for ruminants, minor species, pets and non food-producing
335 animals) should always be ensured. Generally, a confidence level of 95% is adopted when testing
336 difference, 90% for testing equivalence. Use of levels below these thresholds should be justified.

337 **5.4.3. Statistical analysis**

338 The statistical analysis should be performed using models that allow comparing treated and control
339 groups whilst controlling for factors that could influence the outcome of the experiment whenever
340 possible. The class of generalised linear mixed models (McCullagh and Nelder, 1989), known as
341 GLMM, offers a suite of methods flexible enough to fit most of the experimental settings. Typically this
342 type of models includes the treatment and other stratification variables (e.g. age) as fixed factor and
343 blocking factors, if any, as random (e.g. animal/pen location) or as covariates. The response variable
344 is the endpoint under investigation. Under certain conditions a log or other transformations can be
345 needed in order to linearize the relationship with the explanatory factors. Depending on the type of
346 response variable (i.e. continuous, quantal, dichotomic), different kinds of statistical tests and
347 distributional assumptions could be required. The applicant is requested to assess which one is more
348 appropriate and to provide the rationale of the choice. An indicator of quality of fit should always be
349 provided.

350 The analysis of variance is one of the simplest models included in the GLMM class. When using this
351 method, a test for group differences should be carried out preferably using the Scheffé, Dunnet,
352 Tukey (Sachs and Hedderich, 2006) or other comparable tests any time multiple comparisons are
353 performed concurrently. Non-parametric tests may be necessary if only a low number of observations
354 is available, but applicants are encouraged to use sufficient replicates to allow for parametric tests to
355 be performed. When different additives are assessed concurrently using the same control, the
356 statistical evaluation should be done considering only the control and the groups treated with the
357 additive under assessment.

358 **5.5. End-points**

359 The end-points to be measured depend on the design of the tolerance study (see Section 5.2). The
360 minimum required parameters for the different groups of end-points are listed below and may be
361 augmented on a case by case basis.

362 **Performance parameters and related parameters**

363 Feed intake, initial and final body weight, body weight gain, feed to gain ratio, water intake for those
364 additives administered via water. Clinical observations including general health status, behaviour,
365 morbidity and mortality.

366 In addition,

- 367 - for laying hens, laying rate, egg weight, shell quality, feed to egg mass ratio, egg mass/hen
368 per day.
 - 369 - for breeding hens, additionally to those required for laying hens, fertility, hatchability and
370 chick viability.
 - 371 - for dairy animals, milk production (also fat corrected milk), milk composition (total solids,
372 protein, fat and lactose), somatic cell counts, protein, fat and lactose yield.
 - 373 - for sows, number of piglets born, piglets born alive, litter weight at birth and at weaning,
374 number of piglets weaned, weaning to oestrus interval.
 - 375 - for fish, specific growth rate (preferably thermal growth coefficient)
- 376

377

378

379 **Haematology and clinical chemistry**

380 Generally, samples for haematology and blood chemistry analysis should be taken at the end of the
 381 study. Samples should be taken at the start of the trial to establish a baseline in studies involving
 382 cattle for fattening, dairy cows, sows, horses, dogs and cats. Samples should be taken from all
 383 experimental units, and ideally from all animals. However, when total numbers of animals makes it
 384 impractical, subsets of animals/pen should be identified for sampling by a random process carried out
 385 at the beginning of the study. Blood samples should not be pooled.

386 The minimum parameters to be measured are:

387 Total count for erythrocytes, packed cell volume, haemoglobin, mean corpuscular volume, mean
 388 corpuscular haemoglobin, mean corpuscular haemoglobin concentration, total and differential counts
 389 for leukocytes, platelet counts, prothrombin time and fibrinogen (with the exception of the latter two
 390 parameters for fish).

391 Sodium, potassium, chloride, calcium, phosphate, magnesium, total protein, albumin, globulin,
 392 glucose, urea/uric acid (non-protein nitrogen for fish), cholesterol, creatinine, bilirubin, acute phase
 393 proteins, amylase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase,
 394 gamma-glutamyltransferase, alkaline phosphatase and creatine kinase.

395 **Tissues/organs from necropsy**

396 The following organs and tissues from all dose groups should be examined grossly (including weight
 397 of the organs) and preserved for microscopic evaluation: liver, kidneys, spleen, adrenal gland, lung,
 398 stomach, pancreas, small intestine, colon, caecum, thymus, thyroid gland, heart, intestinal lymph
 399 nodes, ovaries/testes. For fish the following organs should be investigated, kidney, liver, spleen,
 400 stomach (where present) and intestinal tract, heart, gonads, gills, bone and eye. Histopathology is
 401 normally required only when indicated by findings in the gross pathology.

402 In all cases, critical end-points known from the toxicological studies in laboratory animals shall be
 403 considered. Any adverse effect detected during efficacy trials shall also be reported in this section. All
 404 deaths should be explained and, if necessary, investigated by gross pathology and histopathology.

405 **5.6. Duration of the tolerance study**

406 The necessary minimum duration of tolerance trials depends on the animal species/category and is
 407 reported below.

Category	Definition of the animal category	Start, from	Duration
Piglets	Young animals having completed the suckling period	Weaning	42 days 35 days if growth rate is ≥ 0.5 kg/day
Pigs for fattening	Animals intended for meat production until day of transport to slaughterhouse	20-35 kg	42 days
Sows	Female animals having been inseminated/mated	From insemination/ mating	From insemination to the end of weaning period (one cycle)

408

409

410

411

412

413

414

Category	Definition of the animal category	Start, from	Duration
Chickens for fattening	Birds raised for fattening	Hatch	35 days
Laying hens	Productive female birds held for egg production purposes	From 20 weeks of age	56 days
Breeder hens	Female birds held for breeding purposes	From 25 weeks of age	56 days
Turkeys for fattening	Birds raised for fattening	Hatch	56 days
Turkeys for breeding purposes	Female and male birds held for breeding purposes	From 32 weeks of age	56 days

415

416 Tolerance studies for chickens for fattening/reared for laying and turkeys for fattening should normally
 417 be performed with one-day-old birds. Tolerance studies on laying hens should be performed normally
 418 during the first third of the laying period.

Category	Definition of the animal category	Start, from	Duration
Calves	Calves which are reared for reproduction, veal production or beef production	1 week of age*	42 days
Cattle	Bovine animals that have completed the weaning period	Full development of rumination but < 6 months of age	42 days
Cows	Lactating cows	4 weeks after beginning of lactation	56 days

419 *for veal production, from 1-3 weeks of age

420 If calves for rearing and cattle for fattening were applied for, a combined study (28 days for each
 421 period) would be considered sufficient. Studies on dairy cows should be performed with high yielding
 422 animals in the first third of the lactation period.

Category	Definition of the animal category	Start, from	Duration
Lambs/kids	Young animals reared for reproduction or meat production	1-4 weeks of age	42 days
Sheep/goats	Lactating animals	4 weeks after beginning of lactation	56 days

423

Category	Definition of the animal category	Start, from	Duration
Salmon and trout	Growing salmonids	Trout: 10 g Salmon: 50 g	90 days or until initial body weight is doubled

Other fin fish	Growing fin fish		90 days or until initial body weight is doubled
Crustaceans	Growing crustaceans		90 days

424

425 In case of tolerance trials for Salmonidae and other fin fish if the additive is intended to be used for
 426 brood stock only, the tolerance tests should be carried out as close to the spawning period as
 427 possible. In that case, tolerance tests should last for 90 days and attention should be paid to the egg
 428 quality and survival of the eggs.

429

Category	Definition of the animal category	Start, from	Duration
Rabbits	Rabbits that are reared for reproduction or meat production	Beginning one week after birth	42 days
Breeding does	Does that have become pregnant at least once		From insemination to the end of weaning period (one cycle)

430

Category	Definition of the animal category	Start, from	Duration
Horses	All categories		42 days

431

Category	Definition of the animal category	Start, from	Duration
Cats			28 days
Dogs			28 days
Other non food-producing animals			28 days

432

433 Where a tolerance study is required for minor species, the duration of the studies (when not indicated
 434 in the tables above) should be at least 28 days for growing animals and 42 days for adult animals.

435 If an additive is applied for a specific and shorter period than that given in the tables above, it should
 436 be administered according to the proposed conditions of use. However, the observation period should
 437 not be shorter than 28 days and should involve the relevant end-points (e.g., for sows for
 438 reproduction the number of piglets born alive when considering the gestation period, or the number
 439 and weight of weaned piglets when considering the lactation period).

440 5.7. Requirement for tolerance studies

441 In principle, tolerance tests should provide evidence of the safety of the additive for each of the target
 442 species/animal categories for which an application is made. It is recognised that it may be unrealistic
 443 to expect studies in all potential target species for which application is made, especially when the
 444 application is for all animal species. Therefore, inter-species extrapolation of data can be applied. In
 445 principle, data can be extrapolated between species if they are physiologically similar. The degree to
 446 which species are physiologically related is judged predominantly in terms of gastrointestinal function.

447 Similarities in metabolism also are considered. In general, the extrapolation is limited between animals
448 which are kept for the same purpose, i.e., meat production or reproduction (including milk or egg
449 production).

450 For the purpose of this guidance, the following food-producing animals are considered as major
451 species from which safety data is normally extrapolated: chicken (*Gallus gallus* ssp. *domesticus*), pig
452 (*Sus scrofa* ssp. *domesticus*), cattle (*Bos taurus*) and Salmonidae (*Salmo salar* or *Onchorynchus*
453 *mykiss*).

454 The number of tolerance studies needed to demonstrate the safety for the target species will depend
455 on the target species for which application is made:

- 456 - If the application is for all animal species, tolerance studies should be provided in salmonids
457 and with at least three major terrestrial animal species representing different
458 physiologic/metabolic capacities and should include chickens for fattening, piglets and dairy
459 cows.
- 460 - If the application is for all terrestrial animal species, tolerance studies should be provided with
461 at least three major animal species representing different physiologic/metabolic capacities and
462 should include chickens for fattening, piglets and dairy cows. If the margin of safety (the ratio
463 of tolerated to maximum proposed use level) is similar between these species, no further
464 studies in other species would be required.
- 465 - If the application is restricted to all poultry/avian species, then tolerance studies should be
466 provided with chickens for fattening and laying hens. In order to cover species for breeding,
467 an additional limited study in breeding hens considering only performance end-points (see
468 Section 5.5) should be submitted. Tolerance data from chickens or turkeys for fattening are
469 generally taken to include chickens reared for laying or turkeys reared for breeding,
470 respectively.
- 471 - If the application is restricted to all pigs/porcine species, then tolerance studies should be
472 submitted for weaned piglets and sows. Tolerance studies for pigs for fattening are not
473 needed if safety for weaned piglets is established.
- 474 - If the application is restricted to ruminant species, then tolerance studies should be submitted
475 in cattle for fattening and dairy cows.
- 476 - If the application covers two animal species (e.g., pigs and poultry), then the requirement
477 would be limited to a total of three tolerance studies including both species and covering
478 growing and reproductive animals.
- 479 - If the application is restricted to all fish, then tolerance studies should be submitted in a
480 salmonid (salmon or trout) and another species (e.g., carp, sea bream or sea bass). If the
481 application includes crustaceans, then an additional study in shrimp would be required.
- 482 - If the application is restricted to all pets and non-food producing animals, tolerance studies
483 would be required for cats, dogs and a third species (e.g. a laboratory animal).
- 484 - If the application covers horses, a tolerance study in horses is required unless safety is
485 established for cattle for fattening or dairy cows and pigs for fattening or sows.
- 486 - If the application covers only one animal category (as defined in Annex IV of Regulation (EC)
487 No 429/2008), at least one study in this category is required. The same principle should be
488 applied if an application is for ornamental fish and/or ornamental birds. However, safety for
489 ornamental fish can be extrapolated from studies in salmonids, safety for ornamental birds
490 from studies with poultry species for fattening, in both cases provided a sufficient wide margin
491 of safety⁴ has been shown in the major species.

492 Tolerance data from major species can be used to support the safety for other species as follows,
493 provided a wide margin of safety is established for the major species:

⁴ A sufficiently wide margin of safety generally is at least ten, meaning that a concentration of at least ten times the highest recommended (approved) dose of the additive was tolerated by the major species without any adverse effects. However, for some substances a lower margin of safety may be considered (e.g., organic acids)

Major species	Other species
Chickens for fattening	other poultry for fattening (e.g., turkeys, ducks, goose, pheasants, quail, guinea fowl, ostrich) and ornamental birds
Laying hens	other birds kept for egg production (e.g., ducks, goose, pheasants, quail, guinea fowl)*
Pigs	other porcine species
Calves or cattle	other growing ruminants (e.g., sheep goat, buffalo) at the corresponding developmental stage
Dairy cows	other dairy ruminants (e.g., goat, sheep, buffalo)
Salmon or trout	ornamental fish

* Extrapolation to breeders (including turkeys) is only possible if additional data on breeding end-points are available.

494
495

496 For certain types of additives, the requirements for tolerance studies above may be modified:

- 497 - For nutritional additives where a tolerance study is required, target animal safety data can be
- 498 derived from one study in a target species or laboratory animal.
- 499 - For silage additives for which tolerance studies are required it is usually sufficient to restrict
- 500 tolerance to a ruminant species, normally the dairy cow. Studies involving other species are
- 501 required only when the nature of the ensiled material makes it more appropriate for use with
- 502 non-ruminants or when there are particular concerns when treated silage is used for
- 503 categories other than adult ruminants (e.g., moist corn for pigs or fish silage for fur animals).
- 504 - For coccidiostats, tolerance studies should be performed in the relevant species/category for
- 505 which application is made.

506 5.8. Reporting

507 For each tolerance study, a study report should be submitted describing the objectives, materials and
508 methods, results and conclusions. The initial protocol should be included; any deviations from the
509 protocol should be clearly indicated and justified in the final report. The reports should include the raw
510 data in digital format and detailed results including descriptive statistics, statistical tests and model
511 outcomes. Reports should start with a trial protocol data sheet (Appendix A) followed by the full study
512 report. International units should be used to express the results.

513 It is recommended that the study report follows the structure detailed below and contain the following
514 information. Applicants are encouraged to follow the recommendations of the [EFSA guidance on](#)
515 [statistical reporting](#).

516 **Title:** The title should provide a concise and clear description of the study, including the type of
517 study, the product under assessment and animal species/category.

518 **Summary:** The summary should include the objectives, a description of the design and methods, the
519 main results and the conclusions of the study.

520 **Objectives:** The objectives of the study should be clearly described.

521 **Materials and methods:** methods, apparatus and materials used, details of the species, breed or
522 strain of the animals, their number and the conditions under which they were housed and fed. In
523 particular, the following should be recorded and reported:

524 Ethical statement

- 525 1) Indicate compliance with national or institutional guidelines for the care and use of animals.

526 Animals, housing and husbandry

- 527 2) Animals: species (for aquatic species intended for human consumption: identification should
528 be made by their colloquial name followed in parenthesis by the Latin binomial), breed, age

- 529 (and size/length for aquatic species), initial body weight, sex, identification procedure,
530 physiological stage and general health.
- 531 3) Husbandry conditions: feeding and rearing conditions (pen/tank size, stocking density,
532 temperature, lighting); for aquatic species water quality including water flow rate, water
533 temperature and salinity, where relevant;
- 534 4) Diets: description of manufacture and quantitative composition of the diet(s) in terms of
535 ingredients used, relevant nutrients (calculated and analysed values) and energy (digestible,
536 metabolisable or net).

537 Study design

- 538 5) Study location, dates and responsible individuals.
- 539 6) Study duration.
- 540 7) The type of design of the study (e.g. factorial, stratified, cross-over).
- 541 8) Experimental groups: number of treatment and control groups, numbers of replicates
542 (experimental unit) per group and number of animals per replicate.
- 543 9) The experimental unit (e.g., individual animal, pen) should be indicated.
- 544 10) The basis for the different measurements (e.g., individual animal, pen) should be indicated for
545 each parameter measured.
- 546 11) Rationale for the selection of the number of animals/replicates used (sample size calculation).
547 Power analysis should be provided.
- 548 12) Steps taken to minimise bias including randomisation and blinding (see section 5.1.1 of the
549 [EFSA guidance on statistical reporting](#)).
- 550 13) Test item: intended concentration of the active substance(s) or agent(s) in the feedingstuffs.

551 Experimental procedures

- 552 14) The procedures carried out to the different experimental groups should be detailed. These
553 should include the parameters/end points measured, indicating when and how they were
554 measured, and information on the methods of analysis.
- 555 15) The health of the animals should be monitored, morbidity and mortality (including culling)
556 recorded.
- 557 16) The methodology to correct feed to gain ratio for mortality (including culling) should be
558 reported.

559 Statistical methods

- 560 17) The result of the power analysis should be reported.
- 561 18) The methods to perform statistical analysis should be stated, including those used to handle
562 missing data.
- 563 19) Describe any methods used to assess whether the data met the assumptions of the statistical
564 approach.

565 **Results:** Results of the study should be presented for all end points considered in the study. Tables
566 should be used to summarise the results from treatments.

- 567 20) Health status of the animals, morbidity and mortality including culling. The timing and
568 prevalence of any unexpected/undesirable incident/effect in individuals or groups.
569 Therapeutic/preventive treatments, if any should be recorded. Likely cause of death should be
570 established by a veterinarian and reported.
- 571 21) The report should include data from all animals or experimental units involved in the trials.
572 Cases which cannot be assessed due to a lack or loss of data should be reported, and their
573 distribution within the groups of animals indicated.

- 574 22) Concentration of the active substance(s) or agent(s) in the feedingstuffs should be
575 periodically analysed and reported. A certificate of analysis of the test item used in the study
576 should be provided.
- 577 23) Report the results for each end-point measured/analysis carried out, with a measure of
578 precision (e.g. standard error or confidence interval).
- 579 24) The report should include descriptive statistics plus detailed outcome of any statistical analysis
580 performed for all measured end points and each time-point.
- 581 25) The measurement units should be specified for any result reported.

582 Discussion

- 583 26) Interpretation of the results, taking into account the study objectives and hypotheses and
584 other relevant studies in the literature.
- 585 27) Comments on the study limitations including any potential sources of bias, any limitations of
586 the animal model and the imprecision associated with the results.

587 Conclusions

- 588 28) The conclusions from the study should be drawn considering the objectives of the study, the
589 hypothesis and the outcome of the study.

590 Raw data, certificates of analysis

- 591 29) The raw data should be provided in a form of an electronic database and should be
592 accompanied by a data dictionary containing the description of the variables and the
593 metadata needed to properly analyse them.
- 594 30) All codes, log and complete outputs for the final statistical analysis (i.e. the results and
595 analysis reported) should be provided in electronic format.
- 596 31) The report should include the certificates of analysis for the different analysis performed,
597 reports of the veterinary observations/gross pathology/histopathology, haematology/clinical
598 chemistry, etc.

599 6. Toxicological studies

600 The toxicological studies available for the active substance(s) should be taken into account when
601 assessing the safety for the target species.

602 Depending on structural alerts or other toxicological considerations, genotoxicity studies may be
603 required when the additive is intended for use in long living animals (e.g., pets) and reproduction
604 animals (e.g., cows, sows, breeder hens). This could be achieved by reference to published studies.

605 7. Interactions *in vivo*

606 Any known interactions of the additive with feed materials, other approved additives, or medicinal
607 products should be documented.

608 For those additives which exert their activity mainly by binding (e.g., clays) there is the possibility that
609 the availability of crucial nutrients, micronutrients and other additives could also be affected. It is
610 recognised that it is not practical to consider all possible nutrients/additives. Therefore, it is
611 recommended to measure apparent digestibility of crude protein, zinc, retinyl or tocopheryl esters,
612 thiamin or pyridoxine and an ionophore coccidiostat, the latter in the case the additive is intended to
613 be used in poultry/rabbits. Such studies should be performed with the highest recommended dose of
614 the additive and could be made in the context of a tolerance/efficacy study. For other additives which
615 may have a negative impact on the absorption of nutrients a similar approach should be taken.

616 8. Microbial studies

617 Studies are only required when:

- 618 • the tolerance test give an indication of an adverse effect related to digestive tract
619 disturbances; or
- 620 • an adverse effect on the gut microbiota can otherwise be anticipated; or
- 621 • the additive shows specific antimicrobial activity at the feed concentration; or
- 622 • the additive is an ionophoric coccidiostat.
- 623 For the details on how to perform the studies see the technical [guidance on microbial studies](#).

624 **References**

- 625 EFSA (European Food Safety Authority), 2007. Opinion of the Scientific Committee on a request from
626 EFSA on the introduction of a Qualified Presumption of Safety (QPS) approach for assessment of
627 selected microorganisms referred to EFSA. The EFSA Journal, 2007, 587, 1–16.
- 628 EFSA (European Food Safety Authority), 2014. Guidance on Statistical Reporting. EFSA
629 Journal 2014;12(12):3908, 18 pp., doi:10.2903/j.efsa.2014.3908
- 662 EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Ricci A, Allende A, Bolton D, Chemaly M,
663 Davies R, Girones R, Herman L, Koutsoumanis K, Lindqvist R, Nørrung B, Robertson L, Ru G, Sanaa
664 M, Simmons M, Skandamis P, Snary E, Speybroeck N, Ter Kuile B, Threlfall J, Wahlström H,
665 Cocconcelli PS, Klein G (deceased), Prieto Maradona M, Querol A, Peixe L, Suarez JE, Sundh I, Vlak
666 JM, Aguilera-Gomez M, Barizzone F, Brozzi R, Correia S, Heng L, Istace F, Lythgo C and Fernández
667 Escámez PS, 2017. Scientific Opinion on the update of the list of QPS-recommended biological
668 agents intentionally added to food or feed as notified to EFSA. EFSA Journal 2017;15(3):4664, 177
669 pp. doi:10.2903/j.efsa.2017.4664
- 670 EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2016.
671 Statement of the panel: Analysis of the need for an update of the guidance documents. EFSA
672 Journal 2016;14(5):4473, 8 pp. doi:10.2903/j.efsa.2016.4473
- 673 McCullagh J and Nelder JA, 1989. Generalized Linear Models, Second Edition. Chapman and Hall/CRC
674 Monographs on Statistics & Applied Probability
- 675 Sachs L and Hedderich J, 2006. Angewandte Statistik. Methodensammlung mit R [Taschenbuch].
676 Springer, Berlin 7
- 677 Weber E, 1991. Grundriß der Biologischen Statistik [Gebundene Ausgabe]. Urban & Fischer, Mchn.
678

679 **Abbreviations**

ANOVA	Analysis of Variance
BMDL ₁₀	Benchmark Dose Level 10
BW	Body weight
DM	Dry matter
FI	Feed intake
GLMMs	Generalised Linear Models
GLP	Good Laboratory Practice
GMMs	Genetically Modified Microorganisms
NOAEL	No Observed Adverse Effect Level
OECD	Organisation for Economic Cooperation and Development
QPS	Qualified Presumption of Safety
TTC	Threshold of Toxicological Concern

680

681

Appendix A – Trial Protocol data sheet

682 FOR TERRESTRIAL ANIMALS

Identification of the additive:		Batch number:	
Trial ID:		Location:	
Start date and exact duration of the study:			
Number of treatment groups (+ control(s)):		Replicates per group:	
Total number of animals:		Animals per replicate:	
Dose(s) of the additive/active substance(s)/agent(s) (mg or Units of activity or CFU/kg complete feed or L water)			
Intended:		Analysed:	
+			
Substances used for comparative purposes:			
Intended dose:		Analysed:	
Animal species/category:			
Breed:		Identification procedure:	
Sex:	Age at start:	Body weight at start:	
Physiological stage:		General health:	
Additional information for field trials:			
Location and size of herd or flock:			
Feeding and rearing conditions:			
Method of feeding:			
Diets (type(s)):			
Presentation of the diet: Mash <input type="checkbox"/> Pellet <input type="checkbox"/> Extruded <input type="checkbox"/> Other			
Composition (main feedingstuffs):			
Nutrient content (relevant nutrients and energy content)			
Intended values:			
Analysed values:			
Date and nature of the examinations performed:			
Method(s) of statistical evaluation used:			
Therapeutic/preventive treatments (reason, timing, kind, duration):			
Timing and prevalence of any undesirable consequences of treatment:			
Date	Signature Study Director or Signature of applicant or representative		

683 † In case the concentration of the additive in complete feed/water may reflect insufficient accuracy, the dose of the additive
 684 can be given per animal/day or mg/kg body weight or as concentration in complementary feed.

685

686 FOR AQUATIC ANIMALS

Identification of the additive:	Batch number:	
Trial ID:	Location:	
Start date and exact duration of the study:		
Number of treatment groups (+ control(s)):	Replicates per group:	
Total number of animals:	Animals per replicate:	
Dose(s) of the additive/active substance(s)/agent(s) (mg, Units of activity, CFU/kg complete feed or L water)		
Intended:	Analysed:	
+		
Substances used for comparative purposes:		
Intended dose:	Analysed:	
Route of administration:		
Animal species/category:		
Colloquial name:	Latin binomial:	
Breed:	Identification procedure:	
Sex*:	Age at start:	Body weight at start:
Physiological stage:	General health:	
Fork length at start:	Lighting conditions:	
Water quality including temperature, salinity, O ₂ and CO ₂ :		
Additional information for field trials:		
Location, size and number of tanks or pens at the farm, production volume:		
Feeding and rearing conditions:		
Method of feeding:		
Diets (type(s)):		
Presentation of the diet: Mash <input type="checkbox"/> Pellet <input type="checkbox"/> Extruded <input type="checkbox"/> Live feed <input type="checkbox"/> Other		
Composition (main feedingstuffs):		
Nutrient content (relevant nutrients and energy content of the feed)		
Intended values:		
Analysed values:		
Date and nature of the examinations performed:		
Response measures for efficacy and tolerance:		
Method(s) of statistical evaluation used:		
Therapeutic/preventive treatments (reason, timing, kind, duration):		
Timing and prevalence of any undesirable consequences of treatment:		
Date	Signature Study Director or Signature of applicant or representative	

687 † In case the concentration of the additive in complete feed/water may reflect insufficient accuracy, the dose of the additive
 688 can be given per animal/day or mg/kg body weight or as concentration in complementary feed.

689 * Where possible